Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05117840 · ClinicalTrials.gov registry record
Screening for High Frequency Malignant Disease
A clinical trial of Lung Cancer, sponsored by Guardant Health.
- Active
- Registry status
- 12,000
- Enrollment target
- 20
- Study locations
NCT05117840 is a study of Lung Cancer that is active but no longer recruiting, run by Guardant Health. The registered enrollment target is 12,000 participants, above the 906-participant average among 409 other Lung Cancer trials with a reported enrollment target (1225% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05117840, a study of Lung Cancer, is active but no longer recruiting, sponsored by Guardant Health.
- ACTIVE NOT RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Conditions Studied
Interventions
- DEVICE Low-dose CT scan
Study Locations (20)
Florida
- Central Florida Pulmonary Group, P.A. - Altamonte Springs
- Pulmonary, Critical Care & Sleep Disorders Institute of South Florida - Atlantis
- CTMD Research - Coconut Creek
- Life Arc Research Centers - Coral Gables
- Pulmonary Physicians of South Florida, LLC - Coral Springs
- SIMED Health, LLC - Gainesville
- National Research Institute - Hialeah
- 3Sync Research - Hialeah
- Zenith Clinical Research - Hollywood
California
- Pacific Cancer Medical Center - Anaheim
- Providence St. Joseph Hospital Eureka Cancer Program - Eureka
- SoCal Clinical Research - Fountain Valley
- Advanced Investigative Medicine - Hawthorne
- Cedars-Sinai Medical Center - Los Angeles
- California Medical Research Associates Inc. - Northridge
- Providence Medical Foundation - Santa Rosa
Alabama
- University of Alabama Birmingham Lung Health Center - Birmingham
Arkansas
- Highlands Oncology Group PA - Fayetteville
Connecticut
- Starling Physicians - New Britain
District of Columbia
- George Washington University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05117840
The ClinicalTrials.gov registry entry for NCT05117840 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 12,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 906-participant average among 409 other Lung Cancer trials with a reported enrollment target (1225% higher). The listed sponsor is Guardant Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Low-dose CT scan is the first listed.
NCT05117840 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05117840 about?
NCT05117840 is a clinical study titled "Screening for High Frequency Malignant Disease". The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency ca...
What is the current status of trial NCT05117840?
This trial is currently active not recruiting. The enrollment target is 12,000 participants. The study started on 2022-01-13. Estimated completion is 2026-04-30.
What conditions does trial NCT05117840 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT05117840?
The interventions under investigation include: Low-dose CT scan (DEVICE).
Who is sponsoring clinical trial NCT05117840?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05117840 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.